What does VERNOPHARMA do?

VERNOPHARMA is a pharmacy in Harelbeke. Private Limited, started on 17 November 1990, 1 establishment.

What is the address of VERNOPHARMA?

The registered office of VERNOPHARMA is located at Vlietestraat 60, 8531 Harelbeke.

Is VERNOPHARMA still active?

Yes. According to the CBE (30 October 2026) VERNOPHARMA is active, legal situation “Normale toestand”, started on 17 November 1990.

Is VERNOPHARMA registered on Peppol?

Yes, VERNOPHARMA is registered on the Peppol network with ID 0208:0441952982.

What is the enterprise number of VERNOPHARMA?

The enterprise number of VERNOPHARMA is BE0441952982.

When was VERNOPHARMA founded?

VERNOPHARMA was founded on 17 November 1990.

Is VERNOPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 November 1990; 5 annual accounts filed, latest fiscal year 2025.

How much profit did VERNOPHARMA make in 2025?

VERNOPHARMA recorded a loss after taxes of € 6,342 in financial year 2025.

What is the revenue of VERNOPHARMA?

As a small company, VERNOPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 70,177.

VERNOPHARMA (Private Limited) - Harelbeke - BE0441952982

Dossier VERNOPHARMA, printed on 30 October 2026 from databakkes.be/en/0441952982/vernopharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

VERNOPHARMA from Harelbeke, company number BE0441952982, closed financial year 2025 with a result of € -6,342 after tax. For that financial year VERNOPHARMA recorded a gross margin of € 70,177 and equity of € 122,490. Compared with financial year 2024, the result moved from € 13,353 to € -6,342. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Healthy

€ 122,490

▼ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -6,342

▼ still € 13,353 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 914

▲ 76% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 102,490.

People and assets in 2025

Wage cost

€ 50,277

▲ 9% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt ≈ 23 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 259,999

▲ € 258,633 vs 2024

€ 11,475 is repaid this year. At this pace the long-term loan is gone in ≈ 23 years.

Owed to suppliers

€ 12,283

▼ 76% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 90,330

▲ 56% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 52,690 Gross margin 2022: € 52,690 First fiscal year in the series	€ 64,011 Gross margin 2023: € 64,011 ▲ 21% vs 2022 (€ 52,690) Favourable step	€ 68,306 Gross margin 2024: € 68,306 ▲ 7% vs 2023 (€ 64,011) Favourable step	€ 70,177 Gross margin 2025: € 70,177 ▲ 3% vs 2024 (€ 68,306) Favourable step	▲ 3%
Profit after taxes	€ 9,908 Profit after taxes 2022: € 9,908 First fiscal year in the series	€ 18,323 Profit after taxes 2023: € 18,323 ▲ 85% vs 2022 (€ 9,908) Favourable step	€ 13,353 Profit after taxes 2024: € 13,353 ▼ 27% vs 2023 (€ 18,323) Unfavourable step	€ -6,342 Profit after taxes 2025: € -6,342 ▼ € 19,695 vs 2024 (€ 13,353) Unfavourable step	▼ € 19,695
Equity	€ 97,156 Equity 2022: € 97,156 First fiscal year in the series	€ 115,479 Equity 2023: € 115,479 ▲ 19% vs 2022 (€ 97,156) Favourable step	€ 128,832 Equity 2024: € 128,832 ▲ 12% vs 2023 (€ 115,479) Favourable step	€ 122,490 Equity 2025: € 122,490 ▼ 5% vs 2024 (€ 128,832) Unfavourable step	▼ 5%
Total debts	€ 98,782 Total debts 2022: € 98,782 First fiscal year in the series	€ 97,104 Total debts 2023: € 97,104 ▼ 2% vs 2022 (€ 98,782) Favourable step	€ 153,122 Total debts 2024: € 153,122 ▲ 58% vs 2023 (€ 97,104) Unfavourable step	€ 445,716 Total debts 2025: € 445,716 ▲ 191% vs 2024 (€ 153,122) Unfavourable step	▲ 191%
Cash	€ 72 Cash 2022: € 72 First fiscal year in the series	€ 1,426 Cash 2023: € 1,426 ▲ € 1,354 vs 2022 (€ 72) Favourable step	€ 518 Cash 2024: € 518 ▼ 64% vs 2023 (€ 1,426) Unfavourable step	€ 914 Cash 2025: € 914 ▲ 76% vs 2024 (€ 518) Favourable step	▲ 76%
Land & buildings	-	-	-	€ 289,282 Land & buildings 2025: € 289,282 First fiscal year in the series
Retained profit	€ 77,156 Retained profit 2022: € 77,156 First fiscal year in the series	€ 95,479 Retained profit 2023: € 95,479 ▲ 24% vs 2022 (€ 77,156) Favourable step	€ 108,832 Retained profit 2024: € 108,832 ▲ 14% vs 2023 (€ 95,479) Favourable step	€ 102,490 Retained profit 2025: € 102,490 ▼ 6% vs 2024 (€ 108,832) Unfavourable step	▼ 6%
Bank debt	€ 9,361 Bank debt 2022: € 9,361 First fiscal year in the series	€ 4,694 Bank debt 2023: € 4,694 ▼ 50% vs 2022 (€ 9,361) Favourable step	€ 1,366 Bank debt 2024: € 1,366 ▼ 71% vs 2023 (€ 4,694) Favourable step	€ 259,999 Bank debt 2025: € 259,999 ▲ € 258,633 vs 2024 (€ 1,366) Unfavourable step	▲ € 258,633
Balance sheet total	€ 195,938 Balance sheet total 2022: € 195,938 First fiscal year in the series	€ 212,583 Balance sheet total 2023: € 212,583 ▲ 8% vs 2022 (€ 195,938) Unchanged	€ 281,954 Balance sheet total 2024: € 281,954 ▲ 33% vs 2023 (€ 212,583) Unchanged	€ 568,206 Balance sheet total 2025: € 568,206 ▲ 102% vs 2024 (€ 281,954) Unchanged	▲ 102%

Key figures of VERNOPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to VERNOPHARMA?

What happened at VERNOPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: loss of € 6,342 (▼ € 19,695 vs 2024). filed late Source: NBB ↗
Mar 4, 1991 New establishment in Harelbeke. KBO
Nov 17, 1990 Start of the company according to the CBE. KBO

In short

From € 9,908 profit in 2022 to € 6,342 loss in 2025.

Paid € 12,358 in corporate taxes since 2022.

Best year ever: 2023, with € 18,323 profit.

Original PDFs at the National Bank ↗

Establishments

Establishment units

Physical locations of this company

Registered office

Vlietestraat 60

8531 Harelbeke

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0441.952.982

VAT number

BE 0441.952.982

Registered office

Vlietestraat 60, 8531 Harelbeke

Names & denominations

VERNOPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

17 November 1990

Peppol

Active · Active since 31 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Groothandel in chemische producten voor industrieel gebruik

Groothandel in chemische producten

Overige detailhandel in nieuwe artikelen neg

Overige gespecialiseerde detailhandel in artikelen, andere dan voedingsmiddelen, n.e.g.

View on CBE Public ↗ Annual accounts (NBB) ↗